Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88296694 |
LAW OFFICE ASSIGNED |
LAW OFFICE 121 |
MARK SECTION |
MARK |
http://uspto.report/TM/88296694/mark.png |
LITERAL ELEMENT |
CTX110 |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
MARK STATEMENT |
The mark consists of standard characters, without claim to any particular font style, size or color. |
GOODS AND/OR SERVICES SECTION (005)(current) |
INTERNATIONAL CLASS |
005 |
DESCRIPTION |
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents; gene therapy products, namely, gene transfer,
regulation, modulation and delivery pharmaceuticals; gene editing |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (005)(proposed) |
INTERNATIONAL CLASS |
005 |
TRACKED TEXT DESCRIPTION |
Cells for medical or clinical use; pharmaceutical and biopharmaceutical
agents; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene
transfer, regulation, modulation and delivery pharmaceuticals; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals
for the treatment of cancer; gene editing |
FINAL DESCRIPTION |
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products,
namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer; |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (042)(class added) |
INTERNATIONAL CLASS |
042 |
DESCRIPTION |
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely,
pharmaceutical research and development; |
FILING BASIS |
Section 1(b) |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
APPLICATION FOR REGISTRATION PER CLASS |
275 |
TOTAL FEES DUE |
275 |
SIGNATURE SECTION |
ORIGINAL PDF FILE |
HS_711254634-153536721_._Y483_executed_Declaration_in_Support_of_Application_190801.PDF |
CONVERTED PDF FILE(S)
(1 page) |
\\TICRS\EXPORT17\IMAGEOUT17\882\966\88296694\xml5\ROA0002.JPG |
SIGNATORY'S NAME |
Anders Kassow |
SIGNATORY'S POSITION |
Executive Director IP |
RESPONSE SIGNATURE |
/James Hastings/ |
SIGNATORY'S NAME |
James Hastings |
SIGNATORY'S POSITION |
Attorney of Record, New York State Bar |
SIGNATORY'S PHONE NUMBER |
9149415668 |
DATE SIGNED |
08/01/2019 |
AUTHORIZED SIGNATORY |
YES |
FILING INFORMATION SECTION |
SUBMIT DATE |
Thu Aug 01 16:01:45 EDT 2019 |
TEAS STAMP |
USPTO/ROA-XX.XXX.XX.XX-20
190801160145807490-882966
94-6208fae870bed13e9e2a1a
67c3e72b27e9f2976b1918a0f
3a56337cc8c04e31-CC-01449
025-20190801153536721708 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
To the Commissioner for Trademarks:
Application serial no.
88296694 CTX110(Standard Characters, see http://uspto.report/TM/88296694/mark.png) has been amended as follows:
CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents; gene therapy products, namely, gene transfer, regulation, modulation and delivery
pharmaceuticals; gene editing
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Cells for medical or clinical use;
pharmaceutical and biopharmaceutical agents;
pharmaceutical and biopharmaceutical agents for the treatment of cancer;
gene therapy products, namely, gene transfer, regulation, modulation and
delivery pharmaceuticals;
gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer;
gene editingClass 005 for Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products,
namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer;
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Applicant hereby adds the following class of goods/services to the application:
New: Class 042 for Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development;
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
FEE(S)
Fee(s) in the amount of $275 is being submitted.
SIGNATURE(S)
Declaration Signature
Original PDF file:
HS_711254634-153536721_._Y483_executed_Declaration_in_Support_of_Application_190801.PDF
Converted PDF file(s) (1 page)
Signature File1
Signatory's Name: Anders Kassow
Signatory's Position: Executive Director IP
Response Signature
Signature: /James Hastings/ Date: 08/01/2019
Signatory's Name: James Hastings
Signatory's Position: Attorney of Record, New York State Bar
Signatory's Phone Number: 9149415668
The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and
other federal territories and possessions; and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another
U.S. attorney or a Canadian attorney/agent not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is concurrently
filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to withdraw; (3) the owner/holder has filed a power of
attorney appointing him/her in this matter; or (4) the owner's/holder's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in
this matter.
RAM Sale Number: 88296694
RAM Accounting Date: 08/01/2019
Serial Number: 88296694
Internet Transmission Date: Thu Aug 01 16:01:45 EDT 2019
TEAS Stamp: USPTO/ROA-XX.XXX.XX.XX-20190801160145807
490-88296694-6208fae870bed13e9e2a1a67c3e
72b27e9f2976b1918a0f3a56337cc8c04e31-CC-
01449025-20190801153536721708